日本新薬（4516）のセグメントごとの売上高・利益等
セグメント通期
| 科目 | 年度 | 機能食品 | 医薬品 |
|---|---|---|---|
| 売上高 | 2013/03 | 116億 | 583億 |
| 2014/03 | 132億 +13.3% | 633億 +8.6% | |
| 2015/03 | 137億 +3.6% | 663億 +4.7% | |
| 2016/03 | 137億 +0.5% | 705億 +6.3% | |
| 2017/03 | 135億 -1.9% | 853億 +21% | |
| 2018/03 | 140億 +4.2% | 874億 +2.5% | |
| 2019/03 | 145億 +3.3% | 1002億 +14.7% | |
| 2020/03 | 150億 +3.5% | 1016億 +1.4% | |
| 2021/03 | 154億 +2.6% | 1065億 +4.8% | |
| 2022/03 | 168億 +9.5% | 1207億 +13.3% | |
| 2023/03 | 222億 +31.8% | 1220億 +1.1% | |
| 2024/03 | 232億 +4.3% | 1251億 +2.6% | |
| 2025/03 | 216億 -6.8% | 1387億 +10.8% | |
| 2026/03 | 223億 +3.3% | 1485億 +7.1% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 営業利益 | 2013/03 | 0.89億 | 68.1億 |
| 2014/03 | 1.39億 +56.2% | 79億 +16% | |
| 2015/03 | 3.07億 +120.9% | 82.6億 +4.5% | |
| 2016/03 | 1.59億 -48.2% | 83.9億 +1.6% | |
| 2017/03 | 5.89億 +270.4% | 147億 +75.1% | |
| 2018/03 | 7.28億 +23.6% | 164億 +11.3% | |
| 2019/03 | 9.65億 +32.6% | 197億 +20.4% | |
| 2020/03 | 9.82億 +1.8% | 207億 +5.1% | |
| 2021/03 | 7.74億 -21.2% | 254億 +22.6% | |
| 2022/03 | 5.29億 -31.7% | 322億 +27.1% | |
| 2023/03 | 5.74億 +8.5% | 288億 -10.8% | |
| 2024/03 | 13.9億 +142.7% | 306億 +6.5% | |
| 2025/03 | 12.7億 -8.9% | 335億 +9.5% | |
| 2026/03 | 8.57億 -32.5% | 333億 -0.6% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| セグメント利益 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | - | |
| 2018/03 | - | - | |
| 2019/03 | - | - | |
| 2020/03 | - | - | |
| 2021/03 | 774百万 | 259億 | |
| 2022/03 | 529百万 -31.7% | 322億 +24.3% | |
| 2023/03 | - | - | |
| 2024/03 | - | - | |
| 2025/03 | - | - | |
| 2026/03 | - | - | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 営業利益率 | 2013/03 | 0.8% | 11.7% |
| 2014/03 | 1.1% +0.3% | 12.5% +0.8% | |
| 2015/03 | 2.2% +1.1% | 12.4% -0.1% | |
| 2016/03 | 1.2% -1% | 11.9% -0.5% | |
| 2017/03 | 4.4% +3.2% | 17.2% +5.3% | |
| 2018/03 | 5.2% +0.8% | 18.7% +1.5% | |
| 2019/03 | 6.7% +1.5% | 19.6% +0.9% | |
| 2020/03 | 6.5% -0.2% | 20.4% +0.8% | |
| 2021/03 | 5% -1.5% | 23.8% +3.4% | |
| 2022/03 | 3.1% -1.9% | 26.7% +2.9% | |
| 2023/03 | 2.6% -0.5% | 23.6% -3.1% | |
| 2024/03 | 6% +3.4% | 24.5% +0.9% | |
| 2025/03 | 5.9% -0.1% | 24.2% -0.3% | |
| 2026/03 | 3.8% -2.1% | 22.5% -1.7% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 研究開発費 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | - | |
| 2018/03 | - | - | |
| 2019/03 | 340百万 | 164億 | |
| 2020/03 | 356百万 +4.7% | 136億 -16.6% | |
| 2021/03 | 383百万 +7.6% | 157億 +15.3% | |
| 2022/03 | 404百万 +5.5% | 225億 +42.9% | |
| 2023/03 | 314百万 -22.3% | 238億 +6.1% | |
| 2024/03 | 335百万 +6.7% | 313億 +31.6% | |
| 2025/03 | 344百万 +2.7% | 340億 +8.5% | |
| 2026/03 | 334百万 -2.9% | 364億 +7% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 設備投資額 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | - | |
| 2018/03 | - | - | |
| 2019/03 | 61百万 | 11.8億 | |
| 2020/03 | 157百万 +157.4% | 23.4億 +98.3% | |
| 2021/03 | 124百万 -21% | 24.6億 +5% | |
| 2022/03 | 242百万 +95.2% | 103億 +317.8% | |
| 2023/03 | 189百万 -21.9% | 128億 +25.1% | |
| 2024/03 | 207百万 +9.5% | 162億 +26.3% | |
| 2025/03 | 163百万 -21.3% | 309億 +90.2% | |
| 2026/03 | 257百万 +57.7% | 72.1億 -76.6% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 固定資産増加額 | 2013/03 | 147百万 | 11.9億 |
| 2014/03 | 56百万 -61.9% | 10.2億 -14.3% | |
| 2015/03 | 88百万 +57.1% | 11.5億 +13.3% | |
| 2016/03 | 114百万 +29.5% | 34.4億 +198.8% | |
| 2017/03 | 135百万 +18.4% | 38.1億 +10.8% | |
| 2018/03 | 138百万 +2.2% | 26.7億 -29.9% | |
| 2019/03 | 61百万 -55.8% | 11.8億 -55.8% | |
| 2020/03 | 157百万 +157.4% | 23.4億 +98.3% | |
| 2021/03 | 124百万 -21% | 24.6億 +5% | |
| 2022/03 | - | - | |
| 2023/03 | - | - | |
| 2024/03 | - | - | |
| 2025/03 | - | - | |
| 2026/03 | - | - | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 従業員数 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | - | |
| 2018/03 | - | - | |
| 2019/03 | 144 | 1,646 | |
| 2020/03 | 154 +6.9% | 1,683 +2.2% | |
| 2021/03 | 156 +1.3% | 1,703 +1.2% | |
| 2022/03 | 162 +3.8% | 1,745 +2.5% | |
| 2023/03 | 165 +1.9% | 1,776 +1.8% | |
| 2024/03 | 170 +3% | 1,782 +0.3% | |
| 2025/03 | 176 +3.5% | 1,802 +1.1% | |
| 2026/03 | 174 -1.1% | 1,852 +2.8% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 資産 | 2013/03 | 85.3億 | 710億 |
| 2014/03 | 93.3億 +9.3% | 712億 +0.3% | |
| 2015/03 | 108億 +15.5% | 744億 +4.5% | |
| 2016/03 | 102億 -5.7% | 760億 +2.2% | |
| 2017/03 | 102億 -0.1% | 792億 +4.2% | |
| 2018/03 | 109億 +7.5% | 883億 +11.5% | |
| 2019/03 | 109億 -0.3% | 938億 +6.2% | |
| 2020/03 | 112億 +3.1% | 986億 +5.2% | |
| 2021/03 | 111億 -0.9% | 1124億 +14% | |
| 2022/03 | 134億 +20.8% | 1215億 +8.1% | |
| 2023/03 | 161億 +20% | 1272億 +4.7% | |
| 2024/03 | 144億 -10.5% | 1513億 +18.9% | |
| 2025/03 | 141億 -1.8% | 1757億 +16.1% | |
| 2026/03 | 157億 +10.9% | 2118億 +20.6% | |
| 科目 | 年度 | 機能食品 | 医薬品 |
| 減損損失 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | 766百万 | |
| 2018/03 | - | - | |
| 2019/03 | - | - | |
| 2020/03 | - | - | |
| 2021/03 | - | - | |
| 2022/03 | - | - | |
| 2023/03 | - | - | |
| 2024/03 | - | - | |
| 2025/03 | - | - | |
| 2026/03 | - | - |
セグメント四半期
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
|---|---|---|---|---|---|---|
| 機能食品 | ||||||
| 売上高 | 2014/03 | 31.8億 | 33.5億 | 35.7億 | 30.7億 | 132億 |
| 2015/03 | 34.9億 +9.7% | 35.2億 +5.2% | 36.2億 +1.2% | 30.2億 -1.6% | 137億 +3.6% | |
| 2016/03 | 34.6億 -1.1% | 37.1億 +5.4% | 34.2億 -5.4% | 31.3億 +3.7% | 137億 +0.5% | |
| 2017/03 | 33.8億 -2.3% | 35.4億 -4.5% | 34.7億 +1.5% | 30.8億 -1.8% | 135億 -1.9% | |
| 2018/03 | 34億 +0.6% | 35.6億 +0.5% | 37.4億 +7.8% | 33.3億 +8.4% | 140億 +4.2% | |
| 2019/03 | 37.4億 +10% | 36.6億 +2.6% | 38.3億 +2.4% | 32.7億 -1.8% | 145億 +3.3% | |
| 2020/03 | 37.4億 ±0% | 38.3億 +4.8% | 38.8億 +1.4% | 35.5億 +8.4% | 150億 +3.5% | |
| 2021/03 | 37億 -1% | 38.2億 -0.3% | 40.7億 +5% | 37.9億 +6.8% | 154億 +2.6% | |
| 2022/03 | 40.8億 +10.2% | 40.2億 +5.4% | 45.6億 +12% | 41.7億 +10.1% | 168億 +9.5% | |
| 2023/03 | 52.1億 +27.8% | 54.3億 +34.8% | 61.9億 +35.6% | 53.6億 +28.7% | 222億 +31.8% | |
| 2024/03 | 61.4億 +17.9% | 61.8億 +14% | 58億 -6.3% | 50.3億 -6.2% | 232億 +4.3% | |
| 営業利益 | 2014/03 | -1.12億 | 0.44億 | 1.32億 | 0.75億 | 1.39億 |
| 2015/03 | 0.82億 | 0.93億 +111.4% | 1.23億 -6.8% | 0.09億 -88% | 3.07億 +120.9% | |
| 2016/03 | 1.15億 +40.2% | 0.28億 -69.9% | -0.06億 赤字 | 0.22億 +144.4% | 1.59億 -48.2% | |
| 2017/03 | 0.71億 -38.3% | 2.13億 +660.7% | 2.41億 | 0.64億 +190.9% | 5.89億 +270.4% | |
| 2018/03 | 2.07億 +191.5% | 1.92億 -9.9% | 2.26億 -6.2% | 1.03億 +60.9% | 7.28億 +23.6% | |
| 2019/03 | 1.81億 -12.6% | 2.54億 +32.3% | 2.96億 +31% | 2.34億 +127.2% | 9.65億 +32.6% | |
| 2020/03 | 2.54億 +40.3% | 2.38億 -6.3% | 2.78億 -6.1% | 2.12億 -9.4% | 9.82億 +1.8% | |
| 2021/03 | 1.75億 -31.1% | 1.31億 -45% | 2.42億 -12.9% | 2.26億 +6.6% | 7.74億 -21.2% | |
| 2022/03 | 1.32億 -24.6% | 1.09億 -16.8% | 2.13億 -12% | 0.75億 -66.8% | 5.29億 -31.7% | |
| 2023/03 | 0.68億 -48.5% | 0.69億 -36.7% | 3.54億 +66.2% | 0.83億 +10.7% | 5.74億 +8.5% | |
| 2024/03 | 3.04億 +347.1% | 4.5億 +552.2% | 4.76億 +34.5% | 1.63億 +96.4% | 13.9億 +142.7% | |
| 営業利益率 | 2014/03 | -3.5% | 1.3% | 3.7% | 2.4% | 1.1% |
| 2015/03 | 2.3% | 2.6% +1.3% | 3.4% -0.3% | 0.3% -2.1% | 2.2% +1.1% | |
| 2016/03 | 3.3% +1% | 0.8% -1.8% | -0.2% 赤字 | 0.7% +0.4% | 1.2% -1% | |
| 2017/03 | 2.1% -1.2% | 6% +5.2% | 6.9% | 2.1% +1.4% | 4.4% +3.2% | |
| 2018/03 | 6.1% +4% | 5.4% -0.6% | 6% -0.9% | 3.1% +1% | 5.2% +0.8% | |
| 2019/03 | 4.8% -1.3% | 6.9% +1.5% | 7.7% +1.7% | 7.2% +4.1% | 6.7% +1.5% | |
| 2020/03 | 6.8% +2% | 6.2% -0.7% | 7.2% -0.5% | 6% -1.2% | 6.5% -0.2% | |
| 2021/03 | 4.7% -2.1% | 3.4% -2.8% | 5.9% -1.3% | 6% ±0% | 5% -1.5% | |
| 2022/03 | 3.2% -1.5% | 2.7% -0.7% | 4.7% -1.2% | 1.8% -4.2% | 3.1% -1.9% | |
| 2023/03 | 1.3% -1.9% | 1.3% -1.4% | 5.7% +1% | 1.5% -0.3% | 2.6% -0.5% | |
| 2024/03 | 4.9% +3.6% | 7.3% +6% | 8.2% +2.5% | 3.2% +1.7% | 6% +3.4% | |
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
| 医薬品 | ||||||
| 売上高 | 2014/03 | 144億 | 146億 | 166億 | 176億 | 633億 |
| 2015/03 | 144億 +0.1% | 150億 +2.6% | 186億 +11.7% | 183億 +3.7% | 663億 +4.7% | |
| 2016/03 | 158億 +9.4% | 164億 +9.5% | 206億 +10.9% | 176億 -3.6% | 705億 +6.3% | |
| 2017/03 | 204億 +28.9% | 172億 +4.7% | 283億 +37.1% | 194億 +10.4% | 853億 +21% | |
| 2018/03 | 208億 +2.2% | 219億 +27.1% | 243億 -14.1% | 204億 +5% | 874億 +2.5% | |
| 2019/03 | 241億 +15.6% | 220億 +0.7% | 297億 +22.2% | 244億 +19.7% | 1002億 +14.7% | |
| 2020/03 | 257億 +6.6% | 242億 +9.6% | 268億 -9.6% | 250億 +2.3% | 1016億 +1.4% | |
| 2021/03 | 262億 +2.2% | 241億 -0.3% | 299億 +11.5% | 262億 +5% | 1065億 +4.8% | |
| 2022/03 | 369億 +40.7% | 265億 +10.2% | 302億 +0.8% | 270億 +3% | 1207億 +13.3% | |
| 2023/03 | 304億 -17.6% | 301億 +13.4% | 326億 +8% | 289億 +6.9% | 1220億 +1.1% | |
| 2024/03 | 309億 +1.5% | 301億 +0.1% | 336億 +3.1% | 305億 +5.6% | 1251億 +2.6% | |
| 営業利益 | 2014/03 | 15.1億 | 16.6億 | 21.9億 | 25.4億 | 79億 |
| 2015/03 | 7.32億 -51.7% | 11.3億 -32.2% | 38.4億 +75.7% | 25.6億 +0.7% | 82.6億 +4.5% | |
| 2016/03 | 5.21億 -28.8% | 14.5億 +28.3% | 48億 +25.1% | 16.2億 -36.7% | 83.9億 +1.6% | |
| 2017/03 | 43.5億 +735.5% | 18.6億 +28.4% | 108億 +124% | -22.8億 赤字 | 147億 +75.1% | |
| 2018/03 | 48億 +10.4% | 40.6億 +119% | 58.5億 -45.6% | 16.4億 | 164億 +11.3% | |
| 2019/03 | 46.7億 -2.9% | 24.7億 -39.2% | 85.7億 +46.5% | 39.8億 +143.2% | 197億 +20.4% | |
| 2020/03 | 62億 +32.9% | 43.3億 +75.6% | 41.6億 -51.4% | 59.9億 +50.7% | 207億 +5.1% | |
| 2021/03 | 73.5億 +18.5% | 34.9億 -19.5% | 89.8億 +115.7% | 55.5億 -7.4% | 254億 +22.6% | |
| 2022/03 | 164億 +122.8% | 50.9億 +46% | 82.6億 -8.1% | 25.3億 -54.3% | 322億 +27.1% | |
| 2023/03 | 94.4億 -42.4% | 90.7億 +78.3% | 87.9億 +6.5% | 14.7億 -41.8% | 288億 -10.8% | |
| 2024/03 | 103億 +9.2% | 86.9億 -4.2% | 93.5億 +6.4% | 22.9億 +55.3% | 306億 +6.5% | |
| 営業利益率 | 2014/03 | 10.5% | 11.4% | 13.1% | 14.4% | 12.5% |
| 2015/03 | 5.1% -5.4% | 7.5% -3.9% | 20.6% +7.5% | 14% -0.4% | 12.4% -0.1% | |
| 2016/03 | 3.3% -1.8% | 8.8% +1.3% | 23.3% +2.7% | 9.2% -4.8% | 11.9% -0.5% | |
| 2017/03 | 21.4% +18.1% | 10.8% +2% | 38.1% +14.8% | -11.7% 赤字 | 17.2% +5.3% | |
| 2018/03 | 23.1% +1.7% | 18.6% +7.8% | 24.1% -14% | 8% | 18.7% +1.5% | |
| 2019/03 | 19.4% -3.7% | 11.2% -7.4% | 28.9% +4.8% | 16.3% +8.3% | 19.6% +0.9% | |
| 2020/03 | 24.2% +4.8% | 17.9% +6.7% | 15.5% -13.4% | 24% +7.7% | 20.4% +0.8% | |
| 2021/03 | 28% +3.8% | 14.5% -3.4% | 30% +14.5% | 21.1% -2.9% | 23.8% +3.4% | |
| 2022/03 | 44.4% +16.4% | 19.2% +4.7% | 27.3% -2.7% | 9.4% -11.7% | 26.7% +2.9% | |
| 2023/03 | 31% -13.4% | 30.1% +10.9% | 27% -0.3% | 5.1% -4.3% | 23.6% -3.1% | |
| 2024/03 | 33.4% +2.4% | 28.9% -1.2% | 27.8% +0.8% | 7.5% +2.4% | 24.5% +0.9% | |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
